All patients
dMMR PDL1 (CPS < 1) PDL1 (CPS >1) pMMR
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
endometrial cancer, pembrolizumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-775, 2023 0.65 [0.55; 0.77]
0.65 [0.55 ; 0.77 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable PFS (extension)detailed results KEYNOTE-775, 2023 0.56 [0.48; 0.66]
0.56 [0.48 ; 0.66 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-775, 2023 0.56 [0.47; 0.66]
NRG-GY018_dMMR, 2023 0.30 [0.19; 0.48]
NRG-GY018_pMMR, 2023 0.54 [0.41; 0.71]
0.48 [0.36 ; 0.64 ] KEYNOTE-775, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023 3 68% 816 low not evaluable objective responses (ORR)detailed results KEYNOTE-775, 2023 2.97 [2.12; 4.18]
2.97 [2.12 ; 4.18 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable AE (any grade)detailed results KEYNOTE-775, 2023 2.10 [0.19; 23.24]
NRG-GY018_dMMR, 2023 0.51 [0.05; 5.70]
NRG-GY018_pMMR, 2023 1.01 [0.51; 1.98]
1.01 [0.54 ; 1.90 ] KEYNOTE-775, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023 3 0% 1,559 low not evaluable AE (grade 3-5)detailed results KEYNOTE-775, 2023 3.26 [2.19; 4.85]
NRG-GY018_dMMR, 2023 1.93 [1.12; 3.33]
NRG-GY018_pMMR, 2023 1.48 [1.06; 2.07]
2.10 [1.26 ; 3.49 ] KEYNOTE-775, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023 3 77% 1,559 low not evaluable AE leading to death (grade 5)detailed results NRG-GY018_dMMR, 2023 0.22 [0.02; 2.51]
NRG-GY018_pMMR, 2023 3.02 [0.60; 15.11]
0.97 [0.08 ; 12.21 ] NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023 2 68% 709 low not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-775, 2023 7.41 [4.88; 11.26]
7.41 [4.88 ; 11.26 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable SAE (any grade)detailed results KEYNOTE-775, 2023 2.94 [2.20; 3.94]
2.94 [2.20 ; 3.94 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 05:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 77,383
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561